close 73% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Investieren birgt Risiken und ist nicht für alle Anleger geeignet. CFDs sind komplexe Instrumente und gehen wegen der Hebelwirkung mit dem hohen Risiko einher, schnell Geld zu verlieren. 73% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie verstehen, wie CFDs funktionieren und ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
SuchenSuchen
Change languageDeutsch
Dashboard
Home・Aktien・Pharming Group NV
Search

Pharming Group NV

Open

1.43

Kursupdate 7. Jan. 2026, 13:03 UTC

BuySell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.419

Max

1.445

Schlüsselkennzahlen

By Trading Economics

Einkommen

2.9M

7.5M

Verkäufe

4.1M

97M

EPS

0.009

Gewinnspanne

7.758

Angestellte

404

Dividenden

By Dow Jones

Nächstes Ergebnis

2. Apr. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-2M

995M

Vorheriger Eröffnungskurs

1.43

Vorheriger Schlusskurs

1.43

Pharming Group NV Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

6. Jan. 2026, 21:14 UTC

Wichtige Markttreiber

Ventyx Biosciences Gains on Report of Possible $1 Billion Eli Lilly Deal

DJ

Lesen

6. Jan. 2026, 19:23 UTC

Akquisitionen, Fusionen, Übernahmen

OneStream to Go Private Through $6.4 Billion Hg Acquisition

DJ

Lesen

6. Jan. 2026, 17:41 UTC

Wichtige Markttreiber

Blink Charging Shares Rise as EV Chargers Begin Accepting Cryptocurrency

DJ

Lesen

6. Jan. 2026, 15:46 UTC

Akquisitionen, Fusionen, Übernahmen

Advent International Leads InPost Takeover Offer, Sky News Says

DJ

Lesen

6. Jan. 2026, 15:37 UTC

Wichtige Markttreiber

Terrestrial Energy Shares Rise After DOE Agreement For Nuclear Plant Development

DJ

Lesen

6. Jan. 2026, 23:46 UTC

Market Talk

Nikkei May Decline After Hitting Record High -- Market Talk

DJ

Lesen

6. Jan. 2026, 23:35 UTC

Market Talk

Gold Edges Higher Amid Ongoing Geopolitical Tensions -- Market Talk

DJ

Lesen

6. Jan. 2026, 23:19 UTC

Market Talk

Greatland 2Q Gold Output Strong, Sales Soft -- Market Talk

DJ

Lesen

6. Jan. 2026, 22:53 UTC

Market Talk

WiseTech, REA and CAR Look Best Insulated From AI Threat -- Market Talk

DJ

Lesen

6. Jan. 2026, 22:03 UTC

Akquisitionen, Fusionen, Übernahmen

Staar Surgical: Merger Proposal Received 14.9M Votes For and 27.3M Against

DJ

Lesen

6. Jan. 2026, 22:03 UTC

Akquisitionen, Fusionen, Übernahmen

Staar Surgical, Which Earlier Reported Stockholder Rejection of Sale to Alcon, Reports Vote Totals

DJ

Lesen

6. Jan. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

DJ

Lesen

6. Jan. 2026, 21:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

DJ

Lesen

6. Jan. 2026, 21:12 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

DJ

Lesen

6. Jan. 2026, 21:12 UTC

Market Talk

Commodity Demand Helps Canada Reduce Reliance on Trade With U.S. -- Market Talk

DJ

Lesen

6. Jan. 2026, 20:59 UTC

Wichtige Markttreiber
Akquisitionen, Fusionen, Übernahmen

Ventyx Biosciences Gains on Report of Possible $1B Eli Lilly Deal

DJ

Lesen

6. Jan. 2026, 20:40 UTC

Akquisitionen, Fusionen, Übernahmen

Acquisition of Ventyx Would Bring Lilly Into Emerging Category of Pills for Inflammation-Related Conditions -- WSJ

DJ

Lesen

6. Jan. 2026, 20:40 UTC

Akquisitionen, Fusionen, Übernahmen

Eli Lilly Nears Deal for Biotech Ventyx -- WSJ

DJ

Lesen

6. Jan. 2026, 20:40 UTC

Akquisitionen, Fusionen, Übernahmen

Deal Could Be Announced Imminently, Sources Say -- WSJ

DJ

Lesen

6. Jan. 2026, 20:40 UTC

Akquisitionen, Fusionen, Übernahmen

Eli Lilly in Advanced Talks to Buy Ventyx Biosciences For Over $1B, Sources Say -- WSJ

DJ

Lesen

6. Jan. 2026, 20:01 UTC

Market Talk

Oil Futures Give Back Post-Venezuela Incursion Gains -- Market Talk

DJ

Lesen

6. Jan. 2026, 19:52 UTC

Market Talk

U.S. Natural Gas Falls Awaiting Colder Weather -- Market Talk

DJ

Lesen

6. Jan. 2026, 19:46 UTC

Akquisitionen, Fusionen, Übernahmen

Under Armour Stock Rises After the 'Warren Buffet of Canada' Boosts Its Stake -- Barrons.com

DJ

Lesen

6. Jan. 2026, 19:08 UTC

Akquisitionen, Fusionen, Übernahmen

OneStream to Go Private Through $6.4B Hg Acquisition

DJ

Lesen

6. Jan. 2026, 18:28 UTC

Akquisitionen, Fusionen, Übernahmen

These Stocks Are Moving the Most Today: Sandisk, Nvidia, AMD, Palantir, OneStream, SoFi, Microchip, and More -- Barrons.com

DJ

Lesen

6. Jan. 2026, 17:20 UTC

Market Talk
Ergebnisse

Financial Services Roundup: Market Talk

DJ

Lesen

6. Jan. 2026, 17:20 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Health Care Roundup: Market Talk

DJ

Lesen

6. Jan. 2026, 15:57 UTC

Market Talk

Crude Futures Ease Back From Early Gains -- Market Talk

DJ

Lesen

6. Jan. 2026, 15:34 UTC

Market Talk
Ergebnisse

Bank of Montreal Expects to Exit 2027 With ROE Hitting 15% Target -- Market Talk

DJ

Lesen

6. Jan. 2026, 15:27 UTC

Market Talk

German Inflation Won't Fall Much Further in 2026 -- Market Talk

DJ

Lesen

Pharming Group NV Prognose

Rating-Konsens

By TipRanks

0 ratings

0

Buy

0

Halten

0

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pharming Group NV – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
help-icon Live chat